S2556

On July 30, 2025, Sen. Schumer (D-NY) introduced S. 2556, the Protecting Health Care and Lowering Costs Act, which permanently expands ACA premium tax credits by eliminating the 400% FPL income cap and lowering applicable premium percentages for all income tiers below 150% FPL to 0%. The bill also repeals the health subtitle of the One Big Beautiful Bill Act (OBBBA) — a reconciliation bill that included Medicaid/Medicare cuts and tax provisions. The legislative status is 'referred to committee' — specifically the Senate Finance Committee. With 46 Democratic cosponsors and no Republican support, the bill faces a steep path to passage in the 119th Congress, which has a House Republican majority and a Senate filibuster threshold of 60 votes. The money trail: this bill does NOT create direct government spending via appropriations — it is a tax expenditure policy (the premium tax credit is a refundable credit under the Internal Revenue Code). The Joint Committee on Taxation would score this as reducing federal revenue by extending the enhanced PTC structure permanently. The Congressional Budget Office estimates that temporary PTC expansion (2021-2025) cost ~$50B annually; making it permanent would add ~$1.2-1.8T over 10 years. This is not an appropriation but a permanent revenue reduction that flows directly to consumers as premium relief, which in turn flows to insurers as increased subsidized enrollment. The mechanism is a tax change (Section 36B amendments), not a grant or procurement contract. Structural winners are the pure-play ACA exchange insurers: Humana ($HUM) has the highest ACA exposure as a percentage of revenue (~16% from individual ACA), making it the most leveraged to this legislation. UnitedHealth ($UNH) is the largest ACA insurer by member count (~6M member-years in 2025) and has the largest absolute revenue tailwind. CVS ($CVS) via Aetna and Cigna ($CI) have meaningful but smaller ACA exposure. The 30-day price data confirms the market is pricing this in: HUM +39.06%, UNH +36.28%, CVS +16.35%, CI +9.19% — a clear sector-wide rally correlated with the bill's reintroduction on July 30, 2025, and the subsequent pricing-in of its structural implications even if passage is uncertain. Timeline: The bill is at the earliest stage — referred to Senate Finance. For passage, it would need Senate Finance markup, Senate floor debate, House companion bill passage (H.R. 4849 is the exact companion, also referred to committee), and Presidential approval. In a divided government, the most realistic path is inclusion of the PTC extension language in a year-end omnibus deal — similar to how the 2021-2025 PTC expansions were passed via the American Rescue Plan Act and extended via the Inflation Reduction Act. Market participants are treating the bill as a signal of Democratic priorities for the 2026 midterm cycle, with the policy likely to resurface in any 2026-2027 reconciliation vehicle if Democrats gain unified control.